Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm Mason

Showing results (61-70 of 71) with videos related to

Pageof 8
Sort By:
British Journal of Cancer|July 17, 2020
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancerSian M Noble, Kirsty Garfield, J Athene Lane, et al.
Critical Reviews in Oncology/Hematology|June 21, 2015
Prostate Cancer Unit Initiative in Europe: A position paper by the European School of OncologyRiccardo Valdagni, Hendrik Van Poppel, Michael Aitchison, et al.
European Urology|May 8, 2021
A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate CancerThomas Van den Broeck, Daniela Oprea-Lager, Lisa Moris, et al.
European Urology|July 7, 2020
Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330]David E Neal, Chris Metcalfe, Jenny L Donovan, et al.
European Urology|October 11, 2016
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT TrialThomas J Johnston, Greg L Shaw, Alastair D Lamb, et al.
European Urology|November 28, 2019
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E Neal, Chris Metcalfe, Jenny L Donovan, et al.
The New England Journal of Medicine|March 13, 2023
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
Health Technology Assessment (Winchester, England)|August 11, 2020
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCTFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
European Urology|February 21, 2022
Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER ConsortiumKatharina Beyer, Lisa Moris, Michael Lardas, et al.
European Urology Focus|May 10, 2021
Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysisMichael Lardas, Nikos Grivas, Thomas P A Debray, et al.
Pageof 8

Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
British Journal of Cancer|July 17, 2020
The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancerSian M Noble, Kirsty Garfield, J Athene Lane, et al.
Critical Reviews in Oncology/Hematology|June 21, 2015
Prostate Cancer Unit Initiative in Europe: A position paper by the European School of OncologyRiccardo Valdagni, Hendrik Van Poppel, Michael Aitchison, et al.
European Urology|May 8, 2021
A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate CancerThomas Van den Broeck, Daniela Oprea-Lager, Lisa Moris, et al.
European Urology|July 7, 2020
Erratum to 'Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received' [European Urology 77 (2020) 320-330]David E Neal, Chris Metcalfe, Jenny L Donovan, et al.
European Urology|October 11, 2016
Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT TrialThomas J Johnston, Greg L Shaw, Alastair D Lamb, et al.
European Urology|November 28, 2019
Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment ReceivedDavid E Neal, Chris Metcalfe, Jenny L Donovan, et al.
The New England Journal of Medicine|March 13, 2023
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate CancerFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
Health Technology Assessment (Winchester, England)|August 11, 2020
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCTFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
European Urology|February 21, 2022
Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER ConsortiumKatharina Beyer, Lisa Moris, Michael Lardas, et al.
European Urology Focus|May 10, 2021
Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysisMichael Lardas, Nikos Grivas, Thomas P A Debray, et al.
Pageof 8